Biotechnology company Moderna Inc (Nasdaq: MRNA) revealed on Wednesday that the European Commission has approved an agreement to secure 80 million doses of mRNA-1273, the company's COVID-19 vaccine candidate.
Under the terms of the proposed agreement, Moderna said the European Commission has the option to increase its purchase of mRNA-1273, from 80 million doses to a total of up to 160 million doses.
On approval by the European Medicines Agency (EMA) human medicines committee (CHMP), Moderna also stated that delivery of the vaccine could begin as early as the first quarter 2021. CHMP reportedly began a rolling review of mRNA-1273 on 17 November 2020.
Moderna added that it is working with its strategic manufacturing partners, Lonza of Switzerland and ROVI of Spain, for manufacturing and fill-finish outside of the US. This is a dedicated supply chain to support Europe and countries other than the US that enter into purchase agreements with Moderna.
The company also said that it remains on track to manufacture 500 million to one billion doses globally in 2021.
If the relevant regulatory approvals are granted, Moderna expects to begin shipping mRNA-1273 to the European Union beginning in December 2020, it concluded.
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma